Rigel Pharmaceuticals (RIGL) Receivables - Other (2025 - 2026)
Rigel Pharmaceuticals (RIGL) recorded quarterly Receivables - Other of $1.0 million in Q1 2026, up 11.11% quarter-over-quarter from $900000.0 in Q4 2025, and up 1654.39% on a YoY basis from $57000.0 in Q1 2025.
Rigel Pharmaceuticals (RIGL) Receivables - Other (2025 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Receivables - Other history runs 2 years deep, the most recent figure standing at $1.0 million for Q1 2026.
- In Q1 2026, Receivables - Other rose 1654.39% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $1.0 million (up 1654.39% YoY), while the FY2025 annual figure was $900000.0, changed N/A from the prior year.
- Receivables - Other was $1.0 million for Q1 2026 at Rigel Pharmaceuticals, up from $900000.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $1.0 million in Q1 2026 to a low of $57000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Rigel Pharmaceuticals | 603.18 Mn | 456.49 Mn | 54.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.00 Mn |
| Mar 31, 2026 | 1.00 Mn |
| Dec 31, 2025 | 900,000.00 |
| Dec 31, 2025 | 900,000.00 |
| Sep 30, 2025 | 57,000.00 |
| Sep 30, 2025 | 57,000.00 |
| Jun 30, 2025 | 57,000.00 |
| Jun 30, 2025 | 57,000.00 |
| Mar 31, 2025 | 57,000.00 |
| Mar 31, 2025 | 57,000.00 |